Patients ( aged 18 years ) with type 2 diabetes inadequately controlled with conventional insulin treatment were randomly assigned ( 1:1:1 ) , via a computer-generated randomisation sequence with an interactive voice-response system , to receive once-weekly dulaglutide 15 mg , dulaglutide 075 mg , or daily bedtime glargine .